Walter U, Loewenbruck K, Dodel R, Storch A, Trenkwalder C, Hoglinger G
J Neurol. 2024; 271(12):7387-7401.
PMID: 38963440
PMC: 11588812.
DOI: 10.1007/s00415-024-12502-1.
Wang X, Feng Y, Li X, Zhu X, Truong D, Ondo W
Front Neurol. 2020; 11:874.
PMID: 32982913
PMC: 7477377.
DOI: 10.3389/fneur.2020.00874.
Prati P, Bignamini A, Coppo L, Naldi A, Comi C, Cantello R
J Neural Transm (Vienna). 2017; 124(7):869-879.
PMID: 28451942
DOI: 10.1007/s00702-017-1724-9.
Munoz Y, Carrasco C, Campos J, Aguirre P, Nunez M
Parkinsons Dis. 2016; 2016:7049108.
PMID: 27293957
PMC: 4886095.
DOI: 10.1155/2016/7049108.
Bouwmans A, Leentjens A, Mess W, Weber W
Parkinsons Dis. 2016; 2016:4058580.
PMID: 26881179
PMC: 4737005.
DOI: 10.1155/2016/4058580.
Parkin Regulation and Neurodegenerative Disorders.
Zhang C, Hang L, Yao T, Lim K
Front Aging Neurosci. 2016; 7:248.
PMID: 26793099
PMC: 4709595.
DOI: 10.3389/fnagi.2015.00248.
Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease.
Fiala O, Zahorakova D, Pospisilova L, Kucerova J, Matejckova M, Martasek P
PLoS One. 2014; 9(9):e107585.
PMID: 25238391
PMC: 4169530.
DOI: 10.1371/journal.pone.0107585.
Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson's Disease.
Oczkowska A, Kozubski W, Lianeri M, Dorszewska J
Curr Genomics. 2014; 14(8):502-17.
PMID: 24532983
PMC: 3924246.
DOI: 10.2174/1389202914666131210205839.
PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.
Madeo G, Schirinzi T, Martella G, Latagliata E, Puglisi F, Shen J
Mov Disord. 2013; 29(1):41-53.
PMID: 24167038
PMC: 4022284.
DOI: 10.1002/mds.25724.
Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.
Barrett M, Hagenah J, Dhawan V, Peng S, Stanley K, Raymond D
Parkinsonism Relat Disord. 2012; 19(2):186-91.
PMID: 23062841
PMC: 3567285.
DOI: 10.1016/j.parkreldis.2012.09.007.
Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.
Bruggemann N, Hagenah J, Stanley K, Klein C, Wang C, Raymond D
Mov Disord. 2011; 26(5):885-8.
PMID: 21312285
PMC: 3082617.
DOI: 10.1002/mds.23644.
Relation of risk factors and putative premotor markers for Parkinson's disease.
Liepelt-Scarfone I, Behnke S, Godau J, Schweitzer K, Wolf B, Gaenslen A
J Neural Transm (Vienna). 2011; 118(4):579-85.
PMID: 21210286
DOI: 10.1007/s00702-010-0553-x.
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.
Berg D
J Neural Transm (Vienna). 2011; 118(4):613-9.
PMID: 21207077
DOI: 10.1007/s00702-010-0565-6.
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.
Walter U
J Neural Transm (Vienna). 2010; 118(4):607-12.
PMID: 21190047
DOI: 10.1007/s00702-010-0564-7.
Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease.
Berg D
J Neural Transm (Vienna). 2010; 118(3):453-61.
PMID: 20830493
DOI: 10.1007/s00702-010-0469-5.
[Sonography of the parenchyma in Parkinson's disease].
Hagenah J, Seidel G
Nervenarzt. 2010; 81(10):1189-95.
PMID: 20802993
DOI: 10.1007/s00115-010-3025-5.
Prodromal non-motor symptoms of Parkinson's disease.
Pellicano C, Benincasa D, Pisani V, Buttarelli F, Giovannelli M, Pontieri F
Neuropsychiatr Dis Treat. 2009; 3(1):145-52.
PMID: 19300544
PMC: 2654529.
DOI: 10.2147/nedt.2007.3.1.145.
Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review.
Vlaar A, Bouwmans A, Mess W, Tromp S, Weber W
J Neurol. 2009; 256(4):530-8.
PMID: 19224315
DOI: 10.1007/s00415-009-0143-8.
Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency.
Hoeppner J, Prudente-Morrissey L, Herpertz S, Benecke R, Walter U
Eur Arch Psychiatry Clin Neurosci. 2008; 259(2):92-7.
PMID: 18806917
DOI: 10.1007/s00406-008-0840-9.
Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles.
Hagenah J, Konig I, Becker B, Hilker R, Kasten M, Hedrich K
J Neurol. 2007; 254(10):1407-13.
PMID: 17934880
DOI: 10.1007/s00415-007-0567-y.